Table 2 Feasibility of accelerated vaccine development (Institute of Medicine (US) Committee on Issues and Priorities for New Vaccine Development [26]
From: Development of a TB vaccine trial site in Africa and lessons from the Ebola experience
Requirement | Ebola Virus | Tuberculosis |
|---|---|---|
knowledge of clinical signs and symptoms of the disease to allow differentiation from similar syndromes | + | ++ |
Knowledge of pathogen characteristics: strains, serotypes, infectivity, virulence, antigenicity, immunogens | ++ [27] | |
Strains & Serotypes | Â | Â |
Infectivity and Virulence | Â | Â |
Antigenicity | Â | Â |
Immunogens | Â | Â |
Ability to cultivate pathogen | + [30] | ++ |
Identified non-human models of infection, closely mimicking human disease | +++ [31] | ++ [32] |
Knowledge of human immune response to the pathogen (duration, type of response) | + [33] | + [34] |
Definition of the target population | + [35] | ++ [36] |